Robalzotan AstraZeneca.
AstraZeneca (formerly Astra) is developing robalzotan, a 5-HT1A antagonist, for the potential treatment of depression and anxiety. The compound has entered phase II trials, and NDA and MAA filings are expected after 2003 [352095,377656]. In August 2000, Lehman Brothers predicted that the compound had a 20% probability of reaching the market, with a predicted launch date of 2005 [384880].